High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group

Introduction. Osteosarcoma relapse has a poor prognosis, with less than 25% survival at 5 years. We describe the experience of the French Society of Paediatric Oncology (SFCE) with high dose (HD) thiotepa and autologous stem cell transplantation (ASCT) in 45 children with relapsed osteosarcoma. Pati...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Marec-Berard, Perrine, Segura-Ferlay, Céline, Tabone, Marie-Dominique, Pacquement, Helene, Lervat, Cyril, Gentet, Jean-Claude, Schmitt, Claudine, Gaspar, Nathalie, Brugières, Laurence
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Hindawi Publishing Corporation 2014
Pynciau:
Clinical Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3941142/
https://ncbi.nlm.nih.gov/pubmed/24672280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/475067
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg